Alpha 2.0
Login Register
» Articles » PMID: 6301362

Pharmacokinetics of Ceftriaxone in Pediatric Patients with Meningitis

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1983 Feb 1
PMID 6301362
Citations 33
Authors
R W. Steele
L B Eyre
R W Bradsher
R E Weinfeld
I H Patel
J Spicehandler
Affiliations
Soon will be listed here.
Abstract

Pharmacokinetics of ceftriaxone after a single dose of 50 or 75 mg/kg were determined in 30 pediatric patients with bacterial meningitis. Data for doses of 50 and 75 mg/kg, respectively, were as follows (mean +/- standard deviation): maximum plasma concentrations, 230 +/- 64 and 295 +/- 76 mug/ml; elimination rate constant, 0.14 +/- 0.06 and 0.14 +/- 0.04 h(-1); harmonic elimination half-life, 5.8 +/- 2.8 and 5.4 +/- 2.1 h; plasma clearance, 51 +/- 24 and 55 +/- 18 ml/h per kg; volume of distribution, 382 +/- 129 and 387 +/- 56 ml/kg; mean concentration in cerebrospinal fluid 1 to 6 h after infusion, 5.4 and 6.4 mug/ml. A dosage schedule of 50 mg/kg every 12 h for bacterial meningitis caused by susceptible organisms is suggested for pediatric patients over 7 days of age.

Citing Articles

Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia.

Kato H, Hagihara M, Morikawa Y, Asai N, Mikamo H, Iwamoto T Antibiotics (Basel). 2022; 11(8).

PMID: 35892373 PMC: 9331887. DOI: 10.3390/antibiotics11080983.

Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.

Hartman S, Upadhyay P, Hagedoorn N, Mathot R, Moll H, van der Flier M Clin Pharmacokinet. 2021; 60(10):1361-1372.

PMID: 34036552 PMC: 8505376. DOI: 10.1007/s40262-021-01035-9.

Variability in Ceftriaxone Dosing Across 32 US Acute Care Children's Hospitals.

Ferguson R, Herigon J, Lee B, Nakamura M, Newland J J Pediatric Infect Dis Soc. 2021; 10(5):677-681.

PMID: 33528009 PMC: 8163046. DOI: 10.1093/jpids/piab004.

Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis.

Wang Y, Wu Y, Li X, Tian L, Khan M, Tang B Antimicrob Agents Chemother. 2020; 64(11).

PMID: 32816735 PMC: 7577156. DOI: 10.1128/AAC.01412-20.

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children.

Srivastava S, Van Zyl J, Cirrincione K, Martin K, Thomas T, Deshpande D Pediatr Infect Dis J. 2020; 39(12):1092-1100.

PMID: 32773662 PMC: 7654946. DOI: 10.1097/INF.0000000000002857.

References
1.
Bennett J, BRODIE J, BENNER E, KIRBY W . Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966; 14(2):170-7. PMC: 546645. DOI: 10.1128/am.14.2.170-177.1966. View
2.
Shelton S, Nelson J, McCracken Jr G . In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins. Antimicrob Agents Chemother. 1980; 18(3):476-9. PMC: 284026. DOI: 10.1128/AAC.18.3.476. View
3.
Seddon M, Wise R, Gillett A, Livingston R . Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980; 18(2):240-2. PMC: 283977. DOI: 10.1128/AAC.18.2.240. View
4.
Schaad U, McCracken Jr G, Loock C, Thomas M . Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis. 1981; 143(2):156-63. DOI: 10.1093/infdis/143.2.156. View
5.
Bradsher R . Ceftriaxone (Ro 13-9904) therapy of serious infection. Antimicrob Agents Chemother. 1982; 22(1):36-42. PMC: 183670. DOI: 10.1128/AAC.22.1.36. View